Duration of Response (DoR) is defined as the time from randomization to disease progression or death for patients who achieve complete or partial alleviation.

Oncolytic virus (OVs) refers to a generic name for viruses that naturally exist or are genetically edited to selectively kill tumor cells.

This article summarized the latest R&D progress of dobutamine hydrochloride, the Mechanism of Action for dobutamine hydrochloride, and the drug target R&D trends for dobutamine hydrochloride.

Clarity Pharmaceuticals proudly announces the initial patient dosing in their 64Cu/67Cu SAR-Bombesin Phase I/II theranostic trial for patients with metastatic castrate resistant prostate cancer.

Duration of Clinical Benefit (DoCB) is defined as the time from randomization to disease progression or death in patients who achieve complete remission, partial remission, or disease stability for 24 weeks or longer.

REGENXBIO Inc. disclosed further provisional safety information and preliminary effectiveness results from the phase I/II AFFINITY DUCHENNE™ study of RGX-202 aimed at treating Duchenne Muscular Dystrophy.

This article summarized the latest R&D progress of disopyramide phosphate, the Mechanism of Action for disopyramide phosphate, and the drug target R&D trends for disopyramide phosphate.

Transcenta Holding Limited states that it has received the green light from FDA to continue with TranStar 301,This trial is conducted for Osemitamab (TST001) used together with Nivolumab and chemotherapy.

Time to Next Treatment (TTNT) is defined as the period from the start of the treatment to the start of the next line of treatment.

The October release of the Patsnap Bio Sequence Database provides a plethora of enhancements in order to improve your searching experience and elevate the efficiency of your FTO review.

This article summarized the latest R&D progress of dexmedetomidine hydrochloride, the Mechanism of Action for dexmedetomidine hydrochloride, and the drug target R&D trends for dexmedetomidine hydrochloride.

Syndax Pharmaceuticals has reported encouraging preliminary figures following a protocol-defined collective examination of the essential AUGMENT-101 study on revumenib, a front-runner in the class of menin inhibitors.